← Oncology Approval Tracker

FDA DECISION ·

Iclusig

ponatinib · Takeda Pharmaceuticals USA

FDA approvalNew or expanded indicationChronic myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with chronic-phase chronic myeloid leukemia resistant to or intolerant of at least two prior kinase inhibitors, with a response-based reduction in dose for the labeled regimen.

LAMPGEN ANALYSIS

Why it matters

Revised eligibility, introduced a response-adapted schedule for chronic-phase disease and added a 10 mg strength.

What research teams should watch

Set up BCR::ABL1 molecular response monitoring and review vascular risk and dose changes.

PRIMARY RECORDS

Sources